83
Views
17
CrossRef citations to date
0
Altmetric
Review

A review about biomarkers for the investigation of vascular function and impairment in diabetes mellitus

&
Pages 415-419 | Published online: 09 Nov 2016

Abstract

The aim of this review was to analyze the main biomarkers of vascular function and impairment in patients with type 2 diabetes. Medline, SCOPUS, Web of Science, and Google Scholar databases were searched. We concluded that proatherogenic adhesion molecules (soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and soluble E selectin) and inflammatory cytokines (high-sensitivity C-reactive protein, interleukin-6, and tumor necrosis factor-α) were elevated in type 2 diabetes mellitus. Their increased expression and release contribute to the accelerated atherogenesis typical of these patients. For these reasons, the early identification of high levels of these biomarkers will help to establish new strategies to reduce cardiovascular complications.

Introduction

Type 2 diabetes mellitus is responsible for high mortality rates, approximately twice that of the general population: micro- and macrovascular complications have been related to this disease.Citation1 Several epidemiological studies showed a strong relationship between type 2 diabetes and cardiovascular events:Citation2 diabetic patients have an incidence of triple vessel coronary artery disease or multivessel disease significantly higher compared to nondiabetics, and the severity of stenosis and total occlusion of vessels were more commonly seen in diabetic patients.Citation3 This is because type 2 diabetes is involved and importantly implicated in the atherogenic process.Citation4 Atherosclerosis is a well-known disease, where the progressive accumulation of cholesterol within the arterial wall plays the main role; this leads to the genesis of atheromatous plaques with consequent vascular narrowing. The rupture of these atheromatous plaques then leads to vascular occlusion, which may finally result in myocardial infarction, stroke, angina pectoris, or peripheral artery disease.Citation5,Citation6 Hyperglycemia, insulin resistance, hyperinsulinemia, hyperlipidemia (in particular elevated free fatty acids), and hyperhomocysteinemia are important pathophysiological components of type 2 diabetes mellitus that trigger systemic inflammation and impair nitric oxide (NO) bioavailability, with consequent impaired endothelial function.Citation7

This review is aimed to analyze the biomarkers of vascular function and impairment in patients with type 2 diabetes; an early identification of these vascular abnormalities will allow study of new screening and therapeutic strategies in order to try to reduce the incidence of disease complications linked to atherosclerosis, especially in high-risk patients.

Mechanism of endothelial damage in patients with type 2 diabetes

Hyperglycemia

Hyperglycemia, in particular postprandial fluctuations, has been linked to endothelial dysfunction, and, combined with absolute increases in glycemia, contributes to oxidative stress and endothelial impairment. Oral glucose tolerance test is the best experimental technique to estimate pancreatic response to a standardized glucose oral load. Previous published studies reported that Oral Glucose Tolerance Test increased some biomarkers involved in inflammatory response and endothelial impairment, such as high-sensitivity C-reactive protein (Hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular adhesion molecule-1 (sVCAM-1), and soluble E selectin (sE-selectin).Citation8,Citation9 Hyperglycemia enhances the secretion of endothelin-1, a vasoconstrictor, in vitro and decreases NO production in the aorta of diabetic rats and coronary microvessels in humans. Moreover, postprandial glycemia induces glycation of protein, which forms cross-linked proteins termed advanced glycation end products, with consequent synthesis and release of cytokines, vasoadhesion molecules, endothelin-1, and tissue factor.

Insulin resistance and hyperinsulinemia

Under physiologic conditions, other than the hypoglycemic function, insulin has also a hemodynamic action at the endothelial level promoting the release of the precapillary sphincter, inducing vasodilatation.Citation10,Citation11 To do this, insulin directly regulates expression and activation of NO synthase, inducing NO production by endothelial cells. Actually, insulin regulates both vasoconstrictor (endothelin-1) and vasodilator (NO) mediators; in euglycemic patients, the vasodilator effect of insulin prevails, while in insulin-resistant patients, endothelin-1 production is preserved, but NO synthesis is altered.Citation11

Hypertriglyceridemia

Hypertriglyceridemia plays a role in the endothelial damage. We have already demonstrated in two previous studies we conducted that hypertriglyceridemia, in particular postprandial hypertriglyceridemia simulated by an oral fat load, is responsible for an elevated inflammatory state with an increase in metalloproteinase (MMP)-2 and MMP-9 and a decreased nitrites/nitrates ratio.Citation12,Citation13 The endothelial damage derived can cause an impaired release of smooth musculature endothelium-mediated, throughout an impaired release of NO.Citation14

Hyperhomocysteinemia

Hyperhomocysteinemia is linked to cardiovascular diseases.Citation15 Homocysteine is responsible for endothelial cell dysfunction and apoptosis of endothelial and smooth muscle cells involved in the atherothrombotic process.Citation16 Homocysteine structure is characterized by a very reactive thiol group, easily oxidized to produce reactive oxygen species.Citation17 On this basis, we can suppose that homocysteine induces cell dysfunction through autooxidation and oxidative damage. Moreover, homocysteine stimulates the production of several cytokines with proinflammatory action.Citation18

Microalbuminuria

Microalbuminuria has been identified as a strong indicator of increased cardiovascular risk among patients with type 2 diabetes and also in patients without diabetes. Previous publications estimated that microalbuminuria causes a 2.4-fold increased risk for cardiovascular death compared to that in patients without microalbuminuria.Citation19,Citation20 If microalbuminuria is diagnosed, we must consider that cardiovascular risk is higher, and patient requires a more “aggressive” intervention for the prevention of cardiovascular events.Citation21

Inflammatory markers

Inflammation plays a key role in the genesis and progression of atherosclerosis. In patients with type 2 diabetes, the inflammatory markers are higher than those in nondiabetic patients, as already shown in several studies.Citation22

In particular, TNF-α is one of the main characters in the acute phase reaction. It is produced mainly by activated macrophages and also by monocytes, T-cells, smooth muscle cells, adipocytes, and fibroblasts. TNF-α has important proinflammatory properties and regulates the innate and adaptive immunity, cell proliferation, and apoptosis.Citation23 TNF-α is also able to induce proatherogenic lipoprotein changes and to reduce insulin sensitivity.Citation23

Another important inflammatory marker is Hs-CRP, mainly synthesized by hepatocytes; high levels reflect active systemic inflammation. The Multiple Risk Factor Intervention Trial, for example, was the first trial to show a strong link between high Hs-CRP and high mortality from coronary heart disease.Citation24 These data were then confirmed by many other primary prevention, prospective epidemiological trials; in the area where ischemia and necrosis occurred, an increase in inflammatory cytokine has been reported.Citation25 The increase in Hs-CRP seems linked to the extension of infarct and with increased possibility of cardiac rupture.Citation26

On the other hand, myeloperoxidase (MPO) is a leukocyte-derived enzyme, it is the main protein in neutrophils, but it is also present in monocytes. MPO uses H2O2 to generate HOCl, producing reactive oxidant species.Citation27 Other than being a major character in the innate immune response, MPO-derived oxidants contribute to tissue damage during inflammation and atherosclerosis. MPO activates protease cascades, including both proapoptotic and prothrombotic pathways, involved in plaque rupture, and intracoronary thrombus generation during sudden cardiac death.Citation28,Citation29 However, MPO is also involved in several inflammatory-mediated diseases.Citation30

Increased levels of IL-6 have also been also linked to high risk of all-cause mortality. IL-6 is an important mediator in inflammation and has a central role for the acute-phase response.Citation31 IL-6 is mostly produced by adipocytes, fibroblast, endothelial cells, and activated leukocytes and monocytes. IL-6 is a regulator of acute-phase inflammatory response; IL-6 stimulates the synthesis of C-reactive protein (CRP) by liver.Citation32

Serum paraoxonase-1 (PON-1) is associated with high-density lipoprotein and prevents lipoproteins from oxidation. It has a hepatic synthesis and production. PON-1 has a protective action against atherosclerosis. PON-1 has antiatherogenic properties, linked to the enzyme’s ability to prevent low-density lipoprotein (LDL) and high-density lipoprotein oxidation, to reduce macrophage oxidation, to stimulate cholesterol efflux from macrophages, and to reduce oxidative status in atherosclerotic plaques. PON-1 also destroys active lipids in mildly oxidized LDL, with a consequent reduction in inflammatory responses in the artery wall cells. PON-1 also reduces monocyte chemotaxis and adhesion to endothelial cells and inhibits monocyte-to-macrophage differentiation. The absence of PON-1 was linked to an overexpression of adhesion molecules.Citation33 LDL oxidation is the first step in atherosclerosis genesis. The oxidized products are scavenged by macrophages that transform into foam cells, filled with cholesterol esters. They eventually become fatty streaks in the endothelium. Lower PON activity was found in patients with type 2 diabetes with neuropathy and retinopathy.Citation34,Citation35

Endothelial damage markers

Endothelial dysfunction typical of diabetes plays a role in atherosclerotic lesions promoting the upregulation of adhesion molecules, the increase in chemokine secretion and leukocyte adherence, the increase in cell permeability, and an enhanced LDL oxidation, platelet activation, cytokine elaboration, and vascular smooth muscle cell proliferation and migration.Citation36

Nitrate and nitrite are an alternative source for NO. Vasodilation, inhibition of endothelial dysfunction, and inhibition of platelet aggregation are protective mechanisms against cardiovascular diseases.Citation37 NO mediates the regulation of vascular tone, with an increase in cyclic guanosine monophosphate and subsequent relaxation of vascular smooth muscle. NO suppresses systemic plasminogen activator inhibitor-1 (PAI-1) levels; elevated plasma PAI-1 levels are associated with endothelial dysfunction.Citation38 Circulating PAI-1 levels are high in diabetics, contributing to the prothrombotic and proatherosclerotic changes. In addition, plasma PAI-1 levels are elevated in insulin resistance.Citation39

On the other hand, cellular adhesion molecules play an important role in atherosclerosis, mediating margination, adhesion, and migration of circulating mononuclear cells from the blood stream to the extravascular compartment.Citation40 They also activate mononuclear cells to release matrix MMPs, promoting plaque rupture and the initiation of acute coronary syndromes.Citation40

In particular, sICAM-1 is linked to the subsequent incidence of coronary heart disease among healthy men and women.Citation41,Citation42 Two prospective cohort trials showed that levels of sICAM-1 are increased many years before a first myocardial infarction occurs;Citation41 data on sVCAM-1 are not so clear.Citation43 Regarding sE-selectin, instead, it confirmed to be a reliable marker and to be strongly linked to traditional cardiovascular risk factors. E-selectin mediates leukocyte rolling on the endothelium and platelet–leukocyte interaction; it is expressed in activated endothelial cells and acts as an adhesive reactant. On activation, sE-selectin is released into the circulation. Patients with myocardial infarction had increased levels of sE-selectin; moreover, sE-selectin levels are related to blood pressure.Citation44

Matrix MMPs are proteolytic enzymes with the role of mediating changes in extracellular matrix. Humans have 24 matrix MMP genes. Matrix MMPs contribute to vascular remodeling and to the developing of atherosclerotic plaque. The activation of matrix MMPs modifies plaque architecture and may directly participate in the process of plaque rupture.Citation45 MMPs are extremely powerful proteolytic enzymes; thus, their biological actions are controlled by tissue inhibitor of MMPs. Among MMPs, MMP-2 and MMP-9 are the most important in vascular remodeling.Citation46 MMP-2 and MMP-9 are Zn2+-dependent endopeptidases, synthesized and secreted in zymogen form. Increased MMP-2 and MMP-9 activities are associated with destruction of the elastic laminae of arteries and aneurysm formation in animals and humans.Citation47 MMP-2 and MMP-9 are elevated in patients with obesity,Citation48 hypertension,Citation49 type 2 diabetes,Citation50 and acute coronary syndrome.Citation51Citation53 Moreover, plasma MMP-9 levels are a novel predictor of cardiovascular risk in patients with coronary artery disease and stroke.Citation54,Citation55

Conclusion

Proatherogenic adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and inflammatory cytokines (high-sensitivity CRP, IL-6, and TNF-α) are elevated in type 2 diabetes mellitus. Their increased expression and release contribute to the accelerated atherogenesis typical of these patients. For these reasons, the early identification of high levels of these biomarkers will help to establish new strategies to reduce cardiovascular complications.

Disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this article. The authors report no other conflicts of interest in this work.

References

  • WeiMGaskillSPHaffnerSMSternMPEffects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart StudyDiabetes Care1998217116711729653614
  • HaffnerSMLehtoSRönnemaaTPyöräläKLaaksoMMortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctionN Engl J Med199833942292349673301
  • HegdeSSMalleshPYeliSMGadadVMGPMComparative angiographic profile in diabetic and non-diabetic patients with acute coronary syndromeJ Clin Diagn Res201489MC07MC10
  • TousoulisDKampoliAMStefanadisCDiabetes mellitus and vascular endothelial dysfunction: current perspectivesCurr Vasc Pharmacol2012101193222112354
  • KruthHSLipoprotein cholesterol and atherosclerosisCurr Mol Med20011663365311899253
  • CroceKLibbyPIntertwining of thrombosis and inflammation in atherosclerosisCurr Opin Hematol2007141556117133101
  • KampoliAMTousoulisDBriasoulisALatsiosGPapageorgiouNStefanadisCPotential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitusCurr Pharm Des201117374147415822204375
  • DerosaGD’AngeloASalvadeoSAModification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjectsMicrovasc Res201079214414920079360
  • DerosaGD’AngeloASalvadeoSAOral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patientsHorm Metab Res201042181319735057
  • BansalTCGuayATJacobsonJWoodsBONestoRWIncidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunctionJ Sex Med20052196103
  • ZitzmannMTestosterone deficiency, insulin resistance and the metabolic syndromeNat Rev Endocrinol200951267368119859074
  • DerosaGFerrariID’AngeloAOral fat load effects on inflammation and endothelial stress markers in healthy subjectsHeart Vessels200924320421019466522
  • DerosaGFerrariID’AngeloAEffects of a standardized oral fat load on vascular remodeling markers in healthy subjectsMicrovasc Res201080111011520359487
  • DavignonJGanzPRole of endothelial dysfunction in atherosclerosisCirculation200410923 suppl 1III27III3215198963
  • NygårdONordrehaugJERefsumHUelandPMFarstadMVollsetSEPlasma homocysteine levels and mortality in patients with coronary artery diseaseN Engl J Med199733742302369227928
  • HossainGSvan ThienenJVWerstuckGHTDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the development of atherosclerosis in hyperhomocysteinemiaJ Biol Chem200327832303173032712738777
  • StarkebaumGHarlanJMEndothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteineJ Clin Invest1986774137013763514679
  • LazzeriniPESelviELorenziniSHomocysteine enhances cytokine production in cultured synoviocytes from rheumatoid arthritis patientsClin Exp Rheumatol200624438739316956428
  • DinneenSFGersteinHCThe association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literatureArch Intern Med199715713141314189224218
  • JagerAKostensePJRuhéHGMicroalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn StudyArterioscler Thromb Vasc Biol199919361762410073965
  • StehouwerCDSmuldersYMMicroalbuminuria and risk for cardiovascular disease: analysis of potential mechanismsJ Am Soc Nephrol20061782106211116825333
  • HameedIMasoodiSRMirSANabiMGhazanfarKGanaiBAType 2 diabetes mellitus: from a metabolic disorder to an inflammatory conditionWorld J Diabetes20156459861225987957
  • PopaCNeteaMGvan RielPLvan der MeerJWStalenhoefAFThe role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular riskJ Lipid Res200748475176217202130
  • KullerLHTracyRPShatenJMeilahnENRelation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention TrialAm J Epidemiol199614465375478797513
  • RockKLKonoHThe inflammatory response to cell deathAnnu Rev Pathol200839912618039143
  • RashidinejadHHosseiniSMMoazenzadehMRelationship between serum level of high-sensitive C-reactive protein and extension of myocardial involvement in patients with acute myocardial infarctionRom J Intern Med201250321121523330288
  • AruomaOIFree radicals, oxidative stress, and antioxidants in human health and diseaseJ Am Oil Chem Soc199875199212
  • FuXKassimSYParksWCHeineckeJWHypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidaseJ Biol Chem200127644412794128711533038
  • BaldusSHeitzerTEiserichJPMyeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusionFree Radic Biol Med200437690291115304260
  • NauseefWMContributions of myeloperoxidase to proinflamma-tory events: more than an antimicrobial systemInt J Hematol200174212513311594511
  • PapanicolaouDAWilderRLManolagasSCChrousosGPThe pathophysiologic roles of interleukin-6 in human diseaseAnn Intern Med199812821271379441573
  • HeinrichPCCastellJVAndusTInterleukin-6 and the acute phase responseBiochem J199026536216361689567
  • AharoniSAviramMFuhrmanBParaoxonase 1 (PON1) reduces macrophage inflammatory responsesAtherosclerosis2013228235336123582715
  • AbbottCAMacknessMIKumarSBoultonAJDurringtonPNSerum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteinsArterioscler Thromb Vasc Biol19951511181218187583560
  • IkedaYSuehiroTInoueMSerum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitusMetabolism19984755986029591753
  • SinghRBMengiSAXuYJArnejaASDhallaNSPathogenesis of atherosclerosis: a multifactorial processExp Clin Cardiol200271405319644578
  • TangYJiangHBryanNSNitrite and nitrate: cardiovascular risk-benefit and metabolic effectCurr Opin Lipidol2011221111521102328
  • BouchieJLHansenHFeenerEPNatriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen systemArterioscler Thromb Vasc Biol19981811177117799812917
  • PannacciulliNDe MitrioVMarinoRGiorginoRDe PergolaGEffect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjectsObes Res200210871772512181379
  • RossRAtherosclerosis – an inflammatory diseaseN Engl J Med199934021151269887164
  • RidkerPMHennekensCHBuringJERifaiNC-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in womenN Engl J Med20003421283684310733371
  • Porsch-OezçueruemezMKunzDKloerHULuleyCEvaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart diseaseJ Am Coll Cardiol19993471995200110588215
  • de LemosJAHennekensCHRidkerPMPlasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular riskJ Am Coll Cardiol200036242342610933352
  • ThorandBBaumertJDöringAAssociation of cardiovascular risk factors with markers of endothelial dysfunction in middle-aged men and women. Results from the MONICA/KORA Augsburg StudyThromb Haemost200695113414116543972
  • LiuPSunMSaderSMatrix metalloproteinases in cardiovascular diseaseCan J Cardiol200622suppl B25B30B
  • GibbonsGHDzauVJThe emerging concept of vascular remodelingN Engl J Med199433020143114388159199
  • LongoGMXiongWGreinerTCZhaoYFiottiNBaxterBTMatrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysmsJ Clin Invest2002110562563212208863
  • DerosaGFerrariID’AngeloAMatrix metalloproteinase-2 and -9 levels in obese patientsEndothelium200815421922418663625
  • DerosaGD’AngeloACiccarelliLMatrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertensionEndothelium200613322723116840178
  • DerosaGD’AngeloATinelliCEvaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjectsDiabetes Metab200733212913417320450
  • DerosaGCiceroAFScaliseFMetalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromesEndothelium2007141455117364896
  • DerosaGCiceroAFScaliseFMetalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 monthsEndothelium2007144–517518317922333
  • DerosaGD’AngeloAScaliseFComparison between metal-loproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndromeHeart Vessels200722636137018043992
  • BlankenbergSRupprechtHJPoirierOPlasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular diseaseCirculation2003107121579158512668489
  • MontanerJMolinaCAMonasterioJMatrix metalloproteinase-9 pretreatment levels predicts intracranial hemorrhagic complications after thrombolysis in human strokeCirculation2003107459860312566373